/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

A

Ashish M. Kamat

Rutgers, The State University of New Jersey(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

1.1K

Papers

30.7K

Citations

88

h-index

376

i10-index

Ashish M. Kamat is an academic researcher from Rutgers, The State University of New Jersey. The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Urinary and Genital Oncology Studies & Urological Disorders and Treatments. The author has an h-index of 88, co-authored 915 publications.

ORCID: 0000-0003-3546-9928

Research Topics

Bladder and Urothelial Cancer Treatments Urinary and Genital Oncology Studies Urological Disorders and Treatments Epigenetics and DNA Methylation Cancer Immunotherapy and Biomarkers

Papers by this author

works

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

2021 · The Lancet Oncology · 516 citations

https://doi.org/10.1016/s1470-2045(21)00147-9

Arjun Vasant Balar Ashish M. Kamat Girish S. Kulkarni Edward Uchio

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

2020 · The Lancet Oncology · 412 citations

https://doi.org/10.1016/s1470-2045(20)30540-4

Stephen A. Boorjian Mehrdad Alemozaffar Badrinath R. Konety Neal D. Shore

Current best practice for bladder cancer: a narrative review of diagnostics and treatments

2022 · The Lancet · 401 citations

https://doi.org/10.1016/s0140-6736(22)01188-6

Éva Compérat Mahul B. Amin Richard Cathomas Ananya Choudhury

Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group

2016 · Journal of Clinical Oncology · 393 citations

https://doi.org/10.1200/jco.2015.64.4070

Ashish M. Kamat Richard Sylvester Andreas Böhle Joan Palou

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†

2019 · European Urology · 190 citations

https://doi.org/10.1016/j.eururo.2019.09.035

J. Alfred Witjes Marek Babjuk Joaquim Bellmunt H.M. Bruins

EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

2019 · Annals of Oncology · 180 citations

https://doi.org/10.1093/annonc/mdz296

Alan Horwich Marek Babjuk Joaquim Bellmunt H.M. Bruins

Research topics

topics

Bladder and Urothelial Cancer Treatments

Urinary and Genital Oncology Studies

Urological Disorders and Treatments

Epigenetics and DNA Methylation

Cancer Immunotherapy and Biomarkers

Chat about Author

Papers

Chat

Click to start Chat